1. Home
  2. PIPR vs GRFS Comparison

PIPR vs GRFS Comparison

Compare PIPR & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PIPR
  • GRFS
  • Stock Information
  • Founded
  • PIPR 1895
  • GRFS 1940
  • Country
  • PIPR United States
  • GRFS Spain
  • Employees
  • PIPR N/A
  • GRFS N/A
  • Industry
  • PIPR Investment Bankers/Brokers/Service
  • GRFS Biotechnology: Pharmaceutical Preparations
  • Sector
  • PIPR Finance
  • GRFS Health Care
  • Exchange
  • PIPR Nasdaq
  • GRFS Nasdaq
  • Market Cap
  • PIPR 5.2B
  • GRFS 7.2B
  • IPO Year
  • PIPR N/A
  • GRFS 2006
  • Fundamental
  • Price
  • PIPR $369.31
  • GRFS $9.82
  • Analyst Decision
  • PIPR Hold
  • GRFS Hold
  • Analyst Count
  • PIPR 4
  • GRFS 1
  • Target Price
  • PIPR $312.50
  • GRFS $10.30
  • AVG Volume (30 Days)
  • PIPR 121.7K
  • GRFS 507.4K
  • Earning Date
  • PIPR 10-24-2025
  • GRFS 07-28-2022
  • Dividend Yield
  • PIPR 1.57%
  • GRFS 1.46%
  • EPS Growth
  • PIPR 55.41
  • GRFS 132.60
  • EPS
  • PIPR 11.86
  • GRFS 0.53
  • Revenue
  • PIPR $1,597,729,000.00
  • GRFS $8,744,226,659.00
  • Revenue This Year
  • PIPR $13.44
  • GRFS $5.61
  • Revenue Next Year
  • PIPR $14.27
  • GRFS $6.70
  • P/E Ratio
  • PIPR $31.17
  • GRFS $24.59
  • Revenue Growth
  • PIPR 10.68
  • GRFS 9.32
  • 52 Week Low
  • PIPR $202.91
  • GRFS $6.19
  • 52 Week High
  • PIPR $370.10
  • GRFS $11.14
  • Technical
  • Relative Strength Index (RSI)
  • PIPR 73.88
  • GRFS 46.43
  • Support Level
  • PIPR $343.00
  • GRFS $9.63
  • Resistance Level
  • PIPR $352.34
  • GRFS $10.06
  • Average True Range (ATR)
  • PIPR 8.52
  • GRFS 0.19
  • MACD
  • PIPR 2.31
  • GRFS -0.02
  • Stochastic Oscillator
  • PIPR 98.34
  • GRFS 38.46

About PIPR Piper Sandler Companies

Piper Sandler Cos is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities and institutional investors in the United States (U.S.) and internationally. The company provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It generates maximum revenue from Advisory services followed by Equity financing.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: